Clinical Trial Update: Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (RE-LuPSMA, NCT06288113) is evaluating re-treatment with Lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Status: RECRUITING